There are currently six major classes of at least 25 antiretroviral drugs available for the treatment of AIDS. Antiretroviral therapy (ART) regimens for HIV-infected patients have dramatically reduced complication rates and mortality. For most HIV-infected patients, ART regimens consist of a combination of dual nucleoside drugs + a 3rd drug from another class. 1. Nucleoside/nucleotide reverse transcriptase inhibitors: These drugs selectively inhibit the HIV reverse transcriptase enzyme and inhibit HIV replication. Commonly used drugs include emtricitabine, lamivudine, abacavir, tenofovir, and so on. 2. Non-nucleoside reverse transcriptase inhibitors: they mainly act on a certain site of HIV reverse transcriptase to inactivate it. Commonly used are Nevirapine, Doravirine, Efavirenz, etc. 3. Protease inhibitors: These drugs inhibit proteases, i.e., they block the synthesis of proteins required for HIV replication and maturation. Commonly used drugs are ritonavir and lopinavir. 4. Integrase chain transfer inhibitors: commonly used drugs such as raltegravir, elviravir, dolutegravir and bictegravir, adverse reactions include diarrhea, nausea, headache, fever, etc.. 5. Inhibitors of cell entry: such as maraviroc, enfuvirtide, fotifloxacin and so on. 6. Post-adsorption inhibitors: ibalizumab is a monoclonal antibody, administered by intravenous infusion once every 2 weeks; the drug binds to CD4 molecules and does not block viral adsorption, but blocks viral penetration. Patients are advised to use the drug under medical supervision to avoid adverse reactions.